COSCIENS Biopharma Inc
TSX:CSCI

Watchlist Manager
COSCIENS Biopharma Inc Logo
COSCIENS Biopharma Inc
TSX:CSCI
Watchlist
Price: 2.9 CAD -2.03% Market Closed
Market Cap: 9.4m CAD

COSCIENS Biopharma Inc
Common Stock

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

COSCIENS Biopharma Inc
Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
COSCIENS Biopharma Inc
TSX:CSCI
Common Stock
$22.6m
CAGR 3-Years
-57%
CAGR 5-Years
-37%
CAGR 10-Years
-19%
Theratechnologies Inc
TSX:TH
Common Stock
$363.9m
CAGR 3-Years
3%
CAGR 5-Years
5%
CAGR 10-Years
5%
Repare Therapeutics Inc
NASDAQ:RPTX
Common Stock
$490.5m
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Common Stock
$1.1B
CAGR 3-Years
-2%
CAGR 5-Years
3%
CAGR 10-Years
16%
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Common Stock
$1.5B
CAGR 3-Years
11%
CAGR 5-Years
29%
CAGR 10-Years
26%
Spectral Medical Inc
TSX:EDT
Common Stock
CA$93.8m
CAGR 3-Years
3%
CAGR 5-Years
5%
CAGR 10-Years
6%
No Stocks Found

COSCIENS Biopharma Inc
Glance View

Market Cap
9.2m CAD
Industry
Biotechnology

COSCIENS Biopharma Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario. COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The firm is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

CSCI Intrinsic Value
7.08 CAD
Undervaluation 59%
Intrinsic Value
Price

See Also

What is COSCIENS Biopharma Inc's Common Stock?
Common Stock
22.6m USD

Based on the financial report for Sep 30, 2025, COSCIENS Biopharma Inc's Common Stock amounts to 22.6m USD.

What is COSCIENS Biopharma Inc's Common Stock growth rate?
Common Stock CAGR 10Y
-19%

Over the last year, the Common Stock growth was 1%. The average annual Common Stock growth rates for COSCIENS Biopharma Inc have been -57% over the past three years , -37% over the past five years , and -19% over the past ten years .

Back to Top